Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
NICE has called for more evidence from Boehringer Ingelheim on its drug empagliflozin for treating type 2 diabetes in new draft guidance.
Type 2 diabetes is a long-term, progressive condition that causes blood sugar levels to become too high. It occurs when the body is not able to use or produce enough insulin – the hormone that controls blood sugar levels and fat metabolism in the body. Many people with diabetes eventually need help to manage their blood sugar levels.
Empagliflozin (marketed as Jardiance) works by blocking the reabsorption of glucose in the kidneys which is instead passed out of the body in the urine. It is an oral, once-daily medication belonging to a class of drugs called sodium glucose co-transporter (SGLT-2) inhibitors.
https://www.nice.org.uk/news/press-...-needed-on-type-2-diabetes-drug-empagliflozin
Type 2 diabetes is a long-term, progressive condition that causes blood sugar levels to become too high. It occurs when the body is not able to use or produce enough insulin – the hormone that controls blood sugar levels and fat metabolism in the body. Many people with diabetes eventually need help to manage their blood sugar levels.
Empagliflozin (marketed as Jardiance) works by blocking the reabsorption of glucose in the kidneys which is instead passed out of the body in the urine. It is an oral, once-daily medication belonging to a class of drugs called sodium glucose co-transporter (SGLT-2) inhibitors.
https://www.nice.org.uk/news/press-...-needed-on-type-2-diabetes-drug-empagliflozin